Jubilant Life Sciences, a global leader in the pyridine, picolines and nutrition industry, announces a price increase of up to 15% for its Beta Picoline, 3-Cyanopyridine and Vitamin B3 (Niacin & Niacinamide) with immediate effect, for non-contract customers and wherever existing contracts permit.

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 6,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

For more information, please contact:

For Investors

Ravi Agrawal

Jubilant Life Sciences Limited

Ph: +91-120 436 1002

E-mail: ravi_agrawal@jubl.com

Siddharth Rangnekar

CDR India

Ph: +91 22 6645 1209

E-mail: siddharth@cdr-india.com

For Media

Sudhakar Safaya

Jubilant Life Sciences Limited

Ph: +91-120 436 1034

E-mail: sudhakar_safaya@jubl.com

Siddhartha Bhatnagar

Perfect Relations

Ph: +91 9873198502

E-mail: sbhatnagar@perfectrelations.com

Jubilant Life Sciences Limited published this content on 20 December 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 20 December 2016 09:23:10 UTC.

Original documenthttp://www.jubl.com/media-press-details.aspx?mpgid=73&pgid=74&pressid=323

Public permalinkhttp://www.publicnow.com/view/D224BF9AE916793749A56A540535DD6C9C4D2AB2